The Foundation
CREATE KNOWLEDGE – INSPIRING IDEAS!
Stiftung Institut für Herzinfarktforschung (IHF) supports cardiovascular clinical research focusing in particular on investigating patient care and quality standards in day-to-day clinical practice. Simply put, our aim in cardiovascular medicine is to save lives, extend lives, and improve lives.
Our foundation’s activities aim at::
- Preventing acute myocardial infarction and investigating optimal therapies
- Implementing therapeutic guidelines in routine practice
- Applying results from randomized trials to medical practice
- Educating the public about myocardial infarction to shorten the time between event and therapy
ARO – ACADEMIC RESEARCH ORGANIZATION
Stiftung IHF regards itself as an Academic Research Organization (ARO) with non-industry funded cardiovascular research making up a considerable portion of its activities. In this respect, the Foundation sets itself apart from traditional Contract Research Organizations (CRO).
IMPROVE THE QUALITY STANDARDS IN CARDIOLOGY
Our support enables extensive patient registries for acute myocardial infarction, stable coronary artery disease, heart failure, and cardiac arrhythmia as well as randomized trials for new therapy strategies to better treat myocardial infarction. With these investigations, we contribute crucially to assuring highest standards in cardiology.
MORE THAN 20 YEARS OF SUCCESS
For more than 20 years, we at IHF have been convinced that medical advances are not defined by merely relying on pharmacological and device innovations. We believe that registries contribute essentially and provide one of the most important tools.
Comparatively small investments may yield huge benefits. The success of this concept reflects in its positive feedback from patient and specialist organizations, health insurances, and the industry. Not only nationwide but also internationally, the projects and publications of our foundation are well received and highly accepted.
ATTRACTIVE FOR SCIENTISTS, VALUABLE FOR PATIENTS
We greatly care to be attractive for committed researchers and their ambitions. Casually speaking, we like to play our part in a research that may be unconventional and challenging but with the prospects to provide new and valuable stimulation and studies. This will finally result in important benefits for heart disease patients and improved therapies based on extended knowledge. We are, of course, delighted if our registries find supporters of any kind with an open mind and a forward-looking way of thinking.
DRIVING – NOT WAITING
Despite our cooperation with commercial partners we are independent in answering important clinical questions. And if the case calls for it, we even start out at our own expense not yet knowing whether we will be able to ensure overall financing. We find it a lot more important to drive essential and challenging research, including niche projects, if they have the potential to open up new paths. In this context, we find it hard to deny our academic spirit and ambition.
